%0 Journal Article
%T Treatment changes in hemophilia A with chromogenic factor VIII assay implementation.
%A Al Moosawi M
%A Nicolson H
%A Wong SKW
%A Dallas KL
%A Jackson S
%J Res Pract Thromb Haemost
%V 7
%N 2
%D Feb 2023
%M 37063773
%F 5.953
%R 10.1016/j.rpth.2023.100098
%X <B>UNASSIGNED: </B>The one-stage assay (OSA) and the chromogenic assay (CSA) are 2 factor VIII (FVIII) assays used for the diagnosis and classification of hemophilia A. Discrepancies between the 2 assays exist in approximately one-third of patients with mild hemophilia A.<BR><B>UNASSIGNED: </B>The objectives of this study were to report the proportion of patients with mild or moderate hemophilia A and OSA-CSA discrepancies and to report the observed changes in treatment approach prompted by the presence of assay discrepancy. The study aimed to identify OSA:CSA ratio associated with the highest sensitivity for identification of patients in whom modification of treatment approach may be recommended.<BR><B>UNASSIGNED: </B>This is a retrospective cohort study including adult (>18-year-old) patients with mild or moderate hemophilia A who were followed up at the Adult British Columbia Hemophilia Program between January 2013 and March 2019.<BR><B>UNASSIGNED: </B>A total of 75 patients with mild and 23 with moderate hemophilia A based on baseline OSA were included. Overall, 52% of study patients had OSA-CSA discrepancies, and change in treatment approach was observed in 27% of patients with OSA-CSA discrepancy. The OSA:CSA ratio of 1.8 to 3.5 demonstrated the highest area under the receiver operating characteristics curve and sensitivity for identification of patients in which modification of treatment approach may be recommended (AUC 0.75; sensitivity 71%).<BR><B>UNASSIGNED: </B>In our population, OSA-CSA discrepancy was observed in 52% of patients with mild or moderate hemophilia A, and the treatment approach in 27% of these patients had to be modified.